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Abstract
Multiple sclerosis (MS) is characterized by inflammatory demyelination and
deposition of fibrinogen in the central nervous system (CNS). Elevated levels
of a critical inhibitor of the mammalian fibrinolitic system, plasminogen activator
inhibitor 1 (PAI-1) have been demonstrated in human and animal models of MS.
In experimental studies that resemble neuroinflammatory disease, PAI-1 deficient
mice display preserved neurological structure and function compared to wild type
mice, suggesting a link between the fibrinolytic pathway and MS. We previously
identified a series of PAI-1 inhibitors on the basis of the 3-dimensional structure
of PAI-1 and on virtual screening. These compounds have been reported to
provide a number of in vitro and in vivo benefits but none was tested in CNS
disease models because of their limited capacity to penetrate the blood-brain
barrier (BBB). The existing candidates were therefore optimized to obtain CNS-
penetrant compounds. We performed an in vitro screeni...
Document type : Article de périodique (Journal article)
Référence bibliographique
Pelisch, Nicolas ; Dan, Takashi ; Ichimura, Atsuhiko ; Sekiguchi, Hiroki ; Vaughan, Douglas E. ;
et. al. Plasminogen activator inhibitor-1 antagonist TM5484 attenuates demyelination and axonal
degeneration in a mice model of multiple sclerosis. In: PLoS One, Vol. 10, no. 4, p. e0124510
[1-17] (2015)
DOI : 10.1371/journal.pone.0124510
RESEARCH ARTICLE
Plasminogen Activator Inhibitor-1 Antagonist
TM5484 Attenuates Demyelination and
Axonal Degeneration in a Mice Model of
Multiple Sclerosis
Nicolas Pelisch1*, Takashi Dan1, Atsuhiko Ichimura1, Hiroki Sekiguchi1, Douglas
E. Vaughan2, Charles van Ypersele de Strihou3, Toshio Miyata1
1 Department of Molecular Medicine and Therapy, United Centers for Advanced Research and Translational
Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan, 2 Department of
Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America,
3 Service de Nephrologie, Cliniques Universitaires Saint Luc, Brussels, Belgium
* n.pelisch@med.tohoku.ac.jp
Abstract
Multiple sclerosis (MS) is characterized by inflammatory demyelination and deposition of fi-
brinogen in the central nervous system (CNS). Elevated levels of a critical inhibitor of the
mammalian fibrinolitic system, plasminogen activator inhibitor 1 (PAI-1) have been demon-
strated in human and animal models of MS. In experimental studies that resemble neuroin-
flammatory disease, PAI-1 deficient mice display preserved neurological structure and
function compared to wild type mice, suggesting a link between the fibrinolytic pathway and
MS. We previously identified a series of PAI-1 inhibitors on the basis of the 3-dimensional
structure of PAI-1 and on virtual screening. These compounds have been reported to pro-
vide a number of in vitro and in vivo benefits but none was tested in CNS disease models
because of their limited capacity to penetrate the blood-brain barrier (BBB). The existing
candidates were therefore optimized to obtain CNS-penetrant compounds. We performed
an in vitro screening using a model of BBB and were able to identify a novel, low molecular
PAI-1 inhibitor, TM5484, with the highest penetration ratio among all other candidates.
Next, we tested the effects on inflammation and demyelination in an experimental allergic
encephalomyelitis mice model. Results were compared to either fingolimod or 6α-methyl-
prednisolone. Oral administration of TM5484 from the onset of signs, ameliorates paralysis,
attenuated demyelination, and axonal degeneration in the spinal cord of mice. Furthermore,
it modulated the expression of brain-derived neurotrophic factor, which plays a protective
role in neurons against various pathological insults, and choline acetyltransferase, a marker
of neuronal density. Taken together, these results demonstrate the potential benefits of a
novel PAI-1 inhibitor, TM5484, in the treatment of MS.
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Introduction
Multiple sclerosis (MS), a chronic, inflammatory, demyelinating disease of the central nervous
system (CNS), is a leading cause of disability in young, mainly female, adults [1]. Its pathologi-
cal hallmarks are inflammation and demyelination; they follow the entry of fibrinogen into the
CNS, inducing an inflammatory response and axonal damage [2,3].
A link between MS and alterations in the endogenous fibrinolitic system has been identified
previously. In particular, increased plasminogen activator inhibitor 1 (PAI-1) levels in the cere-
brospinal fluid as well as in acute lesions of patients with MS have been described [4,5]. In the
same line of evidence, PAI-1 deficient mice appear to be at least partially protected from chron-
ic relapsing experimental allergic encephalomyelitis (CREAE), a model of MS [6].
Previously, we developed a series of orally active, low molecular PAI-1 inhibitors, relying on
virtual screening and the 3-dimentional structure of the complex of PAI-1 with its inhibitory
peptide [7]. In addition to their predictable anti-thrombotic effects, these compounds have
demonstrated to be valuable in numerous preclinical models, including pulmonary fibrosis,
macrophage infiltration, bone marrow regeneration, and arteriosclerosis [7,8,9,10]. However,
none of these PAI-1 antagonists have been investigated in CNS diseases models because of
their inability to cross the blood brain barrier (BBB). We therefore optimized the existing can-
didates in order to obtain a drug with CNS-penetrant properties.
Traditionally, a series of physicochemical properties, such as low molecular weight, high
lipophilicity (clogP) as well as low polarity (TPSA), are needed to allow effective penetration
into the CNS. We selected a class of PAI-1 inhibitors meeting these properties and analyzed
their ability to cross the BBB using an in vitromodel corresponding with the anatomical situa-
tion of cerebral microvessels [11]. Eventually, we identified, among all other candidates, a
novel, small molecule PAI-1 inhibitor, TM5484, with the highest penetration ratio through the
BBB.
We then explored its therapeutic effects on neuroinflammation, demyelination and axonal
degeneration, using a mouse model of MS. The effects of the PAI-1 inhibitor were compared
with either fingolimod or 6α-methylprednisolone, two drugs currently used to treat patients
with MS [12,13]. In addition, we tested the possibility that TM5484 produces neuroprotection
through the modulation of the brain-derived neurotrophic factor (BDNF), a member of the
neurotrophin family of growth factors known to play a key role in neurons survival, and cho-
line acetyltransferase (ChAT), a marker of neuronal density. A direct link between BDNF and
some components of the fibrinolytic pathway has been documented previously [14], but very
little is known about PAI-1 and BDNF in MS. Our results indicate that a small molecular PAI-
1 inhibitor protects against neuroinflammation, demyelination and axonal degeneration in a
mice model of MS, thus validating TM5484 as a potential therapeutic agent.
Materials and Methods
Reagents
Dimethyl sulfoxide (DMSO) was purchased from Nacalai Tesque (Kyoto, Japan), fingolimod
(FTY720) from Selleck Chemicals (Houston, TX, USA), and 6α-methylprednisolone, propano-
lol and verapamil from Sigma Aldrich (Tokyo, Japan).
TM5484 activity and specificity
TM5484 was developed, as a derivative of the PAI-1 inhibitor TM5441 [9], at the United Cen-
ters for Advanced Research and Translational Medicine (ART), Tohoku University Graduate
School of Medicine, Miyagi, Japan. Its PAI-1 inhibitory activity and specificity were assessed by
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a chromogenic assay as previously described [7,8]. In brief, the reaction mixture includes
0.15 mol/L NaCl, 50 mmol/L Tris-HCl pH 8, 0.2mmol/L CHAPS, 0.1% PEG-6000, 1%
dimethylsulfoxide, 5 nmol/L of either human active PAI-1 (Molecular Innovations, Southfield,
MI), human antithrombin III (Sigma-Aldrich, Saint Louis, MO), or human α2-antiplasmin
(Sigma-Aldrich), 2 nmol/L of either human 2-chain tPA (American Diagnostica Inc, Stanford,
CT), thrombin (Sigma-Aldrich), or plasmin (Sigma-Aldrich), and 0.2 mmol/L of either Spec-
trozyme tPA (Chromogenix, Milano, Italy), chromogenic substrate S-2238 (Sekisui medical,
Tokyo, Japan), or chromogenic substrate S-2251 (Sekisui medical) at a final concentration.
Tested compounds were added at various concentrations and the half-maximal inhibition
(IC50) was calculated by logit-log analysis. TM5484 inhibited PAI-1 activity with an IC50
value of 3.56 mM but did not inhibit α2-antiplasmin.
TM5484 pharmacokinetics and toxicity
TM5484, suspended in a 0.5% carboxymethyl cellulose sodium salt solution, was administered
orally by gavage feeding to male Wistar rats (5 mg/kg; CLEA Japan Inc.). Heparinized blood
samples were collected from the vein before (0 h) and 1, 2, 6, and 24 h after oral drug adminis-
tration. Plasma drug concentration was determined by reverse-phase high-performance liquid
chromatography. Maximum drug concentration time (Tmax), maximum drug concentration
(Cmax), and drug half-life (T1/2) were calculated as 2h, 22.5 μM and 1.7h, respectively. All tox-
icity studies followed the International Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use Harmonized Tripartite Guidelines
at the non-GLP conditions. A repeated-dose toxicity study of TM5484 (30 mg/kg) was con-
ducted for 2 weeks in 5 Crl:CD (SD) male rats: no adverse effects were observed. TM5484 was
negative for the reverse mutation Ames test. The effect of TM5484 on the human ether-a-go-
go-related gene (hERG) electric current was investigated in HEL293 cells, transfected with the
hERG gene: TM5484 had not effect on hERG electric current.
Analysis of compounds penetration and concentration into CNS
In order to determine the ability of compounds to penetrate into CNS we used an in vitro
model of BBB (RBT-24H, BBB Kit, PharmaCo-Cell Company Ltd. Nagasaki, Japan). Verapa-
mil and Propanolol were used as a negative and positive control, respectively. This BBB model
was reconstructed by the culture of both primary rat brain micro vascular endothelial cells and
rat brain pericytes separated by a macroporous Millicell membrane (24 wells, pore size: 3.0 μm,
Millipore, Bedford, MA, USA). Briefly, we pre-incubated the BBB kits at 37 °C in 5% CO2 con-
ditions for 4–5 days, in order to strongly reconstruct the barrier integrity and tight-junctions.
To evaluate the barrier integrity and confirm the functionality of the tight-junctions, trans-
endothelial electrical resistance (TEER) was measured at day 5-post incubation. Assays were
carried out using TEER values in the range of 150-to 300-O cm2 [11]. Once the tight junctions
reach a TEER of 300-O cm2, 0.9 mL PBS-based assay medium was added to blank 24-well cul-
ture plates. Prior to incubation, selected compounds were diluted in DMSO 100%. The com-
pounds suspended in 0.2 mL assay medium were fortified into the apical side and incubated
for 30 min. Next, the medium from both the apical and the basolateral sides were collected and
further analyzed by liquid chromatography–mass spectrometry. Transport was measured by
detecting the amount of compound from the lower (basal, brain-side) compartment and was
calculated using the apparent permeability coefficient (Papp), a formula provided by Phar-
maCo-Cell Company Ltd.
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Experimental animals
All animal experiments conformed to the National Health Guide for the Care and Use of Labo-
ratory Animals and were approved by the Animal Committee at Tohoku University. Studies
were performed on 11-week-old female C57BL/6 mice (n = 8–10, each group) and 10-week-old
Lewis rats (n = 6–8, each group), obtained from SJC, Japan SLC (Hamamatsu, Shizuoka,
Japan). Animals were housed under a 12h light-dark cycle and given regular chow, MF (Orien-
tal Yeast Co., Ltd.). At the onset of paralysis, TM5484 (5 mg/kg), fingolimod (0.5 mg/kg) or
6α-methylprednisolone (5 mg/kg) were given daily by gavage to mice diluted in Carmellose So-
dium (Maruishi, Osaka, Japan) and ultra pure water.
Induction and clinical evaluation of EAE
Experimental autoimmune encephalomyelitis (EAE) was induced in mice as described previ-
ously [15]. Briefly, on day 0, 200 microgramme of myelin oligodendrocyte glycoprotein35–55
(MOG35–55) peptide was injected s.c, twice, in the lower and upper back of the mice, in an
equal volume of complete Freund’s adjuvant (Hooke Laboratories, Inc.). Next, 200 ng of per-
tussis toxin (Hooke Laboratories, Inc.) dissolved in PBS was applied i.p. On day 1, another
200 ng of pertussis toxin was administered. For rats, 200 microgramme of myelin basic pro-
tein69-88 (MBP69-88) was injected (Hooke Laboratories, Inc.) twice, in the lower back on day 0.
Animals were scored for motor paralysis on a daily basis. Disease severity was assessed using a
scale ranging from 0 to 5 (Hooke Laboratories, Inc.): 0, normal; 1, limp tail; 1.5, Limp tail and
hind leg inhibition; 2, Limp tail and weakness of hind legs.; 2.5, Limp tail and dragging of hind
legs; 3, Limp tail and complete paralysis of hind legs; 3.5, Limp tail and complete paralysis of
hind legs and Hind legs are together on one side of body; 4, Limp tail, complete hind leg and
partial front leg paralysis; 4.5, Complete hind and partial front leg paralysis, no movement
around the cage; 5, Mouse is spontaneously rolling in the cage. Mice were typically observed
for 28 days, during which they will remain chronically paralyzed. Rats were observed for three
weeks: all groups including vehicle fully recovered, without relapses.
Quantitative real-time polymerase-chain reaction (qRT-PCR)
Spinal cord was harvested from mice and snap frozen in liquid nitrogen (n = 6–7, each group).
Total RNA was extracted from spinal cord and spleen using ISOGEN (Nippon Gene).
qRT-PCR analysis was performed as described previously [10]. Briefly, qRT-PCR was per-
formed on a LightCycler rapid thermal cycler system using a LightCycler 480 SYBR Green I
Master (Roche Applied Science) according to the manufacturer's instructions. Data were ana-
lyzed by using the comparative Ct method as means of relative quantification, normalized to
an endogenous reference (b-actin, Actb). The sequences of the primers are described below:
Mice Serpine sense: GATGGCTCAGACCAACAAGTTCAA
Mice Serpine antisense: TGGTAGGGCAGTTCCAGGATG
Mice Tnf sense: CTCCAGGCGGTGCTTGTTCC
Mice Tnf antisense: GGCTTGTCACTCGGGGTTCG
Mice Cd11b sense: ATAGTGACATTGCCTTCTTG
Mice Cd11b antisense: ATCTTGGGTTAGGGTTGTTC
Mice Il1b sense: AAATACCTGTGGCCTTGGGC
Mice Il1b antisense: CTTGGGATCCACACTCTCCAG
Mice Il6 sense: CACAGACAGCCACTCACCTC
Mice Il6 antisense: TCCAAAAGACCAGTGATGAT
Mice Il10 sense: CATGGCCCAGAAATCAAGGA
Mice Il10 antisense: GGAGAAATCGATGACAGCGC
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Mice Cd68 sense: AGTGGACATTCTCGGCTCAG
Mice Cd68 antisense: ATGATGAGAGGCAGCAAGAT
Mice BDNF sense: ACGAAGAAAACCATAAGGAC
Mice BDNF antisense: CCACTCGCTAATACTGTCAC
Mice ChAT sense: TCATTAATTTCCGCCGTCTC
Mice ChAT antisense: AGTCCCGGTTGGTGGAGTC
Mice Ccl2 sense: CCTTCTGTGCCTGCTGCTCA
Mice Ccl2 antisense: ACTTGCTGCTGGTGATTCTT
Mice Il17 sense: CAGCAGCGATCATCCCTCAAAG
Mice Il17 antisense: CAGGACCAGGATCTCTTTGCTG
Mice IFNγ sense: TCTGTCTCCTCAACTATTTC
Mice IFNγ antisense: CATCTCCTCCCATCAGCAGC
Mice Actb sense: TGGCACCCAGCACAATGAA
Mice Actb antisense: CTAAGTCATAGTCCGCCTAGAAGCA
Histology
Mice were perfused in the heart with saline 0.9% followed by neutral-buffered formalin 10%
(n = 3-4/group). Slides from different sections of the spinal cord were immersed and fixed
overnight in 10% neutral-buffered formalin. Next, samples were transfered and immersed in a
10, 20 and 30% sucrose solution for consecutive nights. Sections were embedded in O.C.T com-
pounds (Sakura Finetek, Japan) for the subsequent immunostaining study. Four sections of the
spinal cord from each group were examined. Since the clinical manifestations are typically ini-
tiated as limp tail and hind-limb paralysis in this model, we focused on lumbar spinal seg-
ments. Frozen specimens were then incubated overnight at room temperature and stained with
Cd11b for macrophage infiltration (Abcam), myelin basic protein (MBP) for demyelination,
neurofilament non-phosphorylated (SMI-32) for axonal damage, collagen IV for extracellular
matrix depositions (Abcam) and fibrinogen (Funakoshi, Japan). Incubation for 2 hs at room
temperature in corresponding biotinylated goat secondary antibody was performed. For
immunofluorescence, the sections were incubated overnight at room temperature using prima-
ry antibody Iba-1 for microglia activation (Wako Chemicals). After wash in PBS, the sections
were then incubated in corresponding fluorescent goat secondary antibody (Wako Chemicals).
For Cd11b, the number of positive macrophage was quantified as the total cells per selected
area. The area of demyelination was calculated as the percentage of negative staining for MBP
per selected area. As for axonal damage and collagen IV deposition, the positive staining per se-
lected area was analyzed and calculated as the percentage per total area. For Quantification
analysis was assessed by ImageJ TM software (version 1.440, National Institute of Health, Be-
thesda, MD, USA).
Foot print analysis
The footprint test was used to measure and compare the stride length (the mean distance of
forward movement between each stride) of EAE mice with that of TM5484 and fingolimod
treated mice, as previously described [16]. Briefly, to obtain footprints, the hind- and forefeet
of the mice were coated with black non-toxic paint. The floor of the open field box was covered
with white paper. Each mouse was placed in a corner of the open field and allowed to walk
across the paper, leaving a track of footprints. If a mouse didn’t walk forward, the task was con-
sidered a failure. For each step parameter, three values were measured from each run, excluding
footprints made at the beginning and end of the run where the animal was initiating and finish-
ing movement respectively. The mean value of each set of three values was used for analysis.
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Statistical analysis
The significance of the difference between data sets was assessed by the Student’s t-test. Differ-
ences between multiple groups were analyzed by one-way ANOVA test followed by the Tukey
HSD or Dunnett’s test for comparison between treatment groups. All statistical analyses were
performed using the Prism software (version 5.0, GraphPad Software, La Jolla, CA, USA). In
vitro data and in vivo data were expressed as means ± standard error and means ± standard di-
vision, respectively. P<0.05 was considered to be statistically significant.
Results
TM5484 is a PAI-1 inhibitory compound highly penetrating into CNS
We synthesized over 500 derivatives of the lead compound TM5275 and systematically tested
the compounds to identify a candidate able to cross the BBB (S1 Fig). Taking into account the
requirements for a good CNS penetration [17], we selected about 50 compounds with a low
MW, a lipophilicity (clogP)< 4 and a surface area (TPSA)> 75. As shown in Fig 1, a drug
with a Papp above 20 x 10–6 cm/s was considered to have a very good penetration into the
CNS, while a compound with a Papp lower than 10 x 10–6 cm/s was considered a low penetrant
CNS drug. As expected, fingolimod, with a Papp of 56 x 10–6 cm/s, was found at the brain side
Fig 1. In vitroBBB penetration assay. Analysis of the penetration ratio of different compounds using an in vitromodel of BBB. A permeability coefficient
(Papp) above 20 x 10–6 cm/s is considered to provide a very good penetration into the CNS, while a Papp lower than 10 x 10–6 cm/s is consistant with a low
penetrant CNS drug. TM5484 has a 67.6 x 10–6 cm/s permeability coefficient. Verapamil (N.D.) and Propanolol (31.3 x 10–6 cm/s) were used as negative and
positive control, respectively. Data are mean±SD. n = 3 for each compound. N.D. indicates not detectable.
doi:10.1371/journal.pone.0124510.g001
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of the insert. Propanolol, a sympatholytic non-selective beta-blocker, had a Papp of 31.3 x
10–6 cm/s. TM5441 (M.W., 428.8; clogP, 2.39; TPSA, 117.9), had a Papp of 32.1 x 10–6 cm/s.
Further structural optimization of TM5441 generated TM5484 (M.W., 384.7; clogP, 3.07;
TPSA, 108.6) with a Papp of 67.6 x 10–6 cm/s, indicating the highest penetration across the
BBB.
TM5484 attenuates paralysis and motor coordination in a mouse model
of MS
EAE animals developed motor paralysis starting on day 10 or 11-post EAE induction (dpi)
(Fig 2A and 2B). Mice given TM5484 at 5 mg/kg/d from the onset of signs had a significant
amelioration of paralysis at the end of the experiment. In preliminary experiments we discovered
that 5 mg/kg for TM5484 was the minimum effective dose for mice. Fingolimod (0.5 mg/kg) and
6α-methylprednisolone (5 mg/kg) also ameliorated the motor paralysis as compared to EAE
group (Fig 2A and 2B). Dosage of these two drugs was chosen on the basis of previous studies
[18,19].
We also assessed the effects of TM5484 on the impaired motor coordination caused by EAE
induction. Mice were subjected to footprint analysis to assess the stride length. We found that
EAE untreated mice had shorter stride lengths as compared to controls (Fig 2C). Most of this
EAE untreated mice exhibited a dragging pattern due to severe paralysis of the hind legs. Oral
administration of TM5484 as well as fingolimod significantly preserved the stride length of
EAE mice.
TM5484 mitigates inflammation, modulates BDNF and ChAT
Previous studies reported that PAI-1 not only promotes leukocyte adhesion and migration but
also plays a role in the inflammatory response and cell infiltration in MS [20,21,22]. We there-
fore investigated the potential effects of TM5484 on these processes in the CNS as well as in the
periphery, using quantitative RT-PCR. As expected, gene expression of tumor necrosis alpha
(TNF-α), interleukin-6 (IL-6) and chemokine Ligand-2 (Ccl2) were increased in EAE untreat-
ed mice, measured at dpi. 28 (Fig 3 and S2 Fig). Cd68, a marker of microglia activation, was
also elevated. TM5484 or fingolimod, started from the onset of paralysis, provided similar re-
ductions on these inflammatory markers in the spinal cord and spleen. Expression of IL-10, an
antiinflammatory cytokine, was upregulated by TM5484 and fingolimod (S2 Fig). Elevation of
PAI-1 mRNA expression in EAE mice was also prevented by TM5484.
We next examined whether TM5484 could also preserve brain tissue. In line with previous
studies [23,24], BDNF as well as ChAT expression were significantly reduced in the spinal cord
of EAE mice (Fig 3, panel at the bottom of the right column and S3 Fig). Importantly, TM5484
treatment was able to up-regulate levels of BDNF and ChAT similar to those of control group.
In contrast to previous reports [25], fingolimod did not restore BDNF expression in the spinal
cord of EAE mice.
TM5484 ameliorates demyelination, axonal degeneration and collagen
IV deposition
Extensive accumulation of macrophage and microglia activation in the spinal cord of EAE
mice was demonstrated by increased Cd11b and Iba-1 staining (Fig 4A and S4 Fig). However,
this was significantly reduced by oral administration of TM5484 and fingolimod.
Anti-MBP staining in spinal cord was then used to ascertain the effects of TM5484 on de-
myelination. Unsurprisingly, representative cross sections of the spinal cord revealed a higher
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Fig 2. Clinical score and foot print assay.Mice were injected with myelin oligodendrocyte glycoprotein35-55 peptide in an equal volume of complete
Freund’s adjuvant. TM5484 (5 mg/kg/d) given from the onset of symptoms significantly reduced the paralysis score compared to EAE untreated mice.
Fingolimod (A, 0.5 mg/kg) and 6-αmethylprednisone (B, 5 mg/kg/d) attenuated the paralysis score to the level observed with TM5484. C, TM5484 attenuates
EAE-induced motor coordination impairment. Each mouse was placed in a corner of the open field and allowed to walk across the paper, leaving a track of
footprints. For each step parameter, footprints made at the beginning and end of the run were excluded. Stride length of EAE untreated mice was considered
0 cm due to dragging. TM5484 treated mice had a stride length of 4.12 cm at dpi. 28, while Fingolimod treated animals showed a stride length of 5.48. The
mean value of each set of three values was used for analysis. Data are shown as the means and corresponding SD. **P<0.01 or ***P<0.001 Vehicle vs
TM5484, †P < 0.01, ‡P < 0.001 Vehicle vs Fingolimod or 6-αmethylprednisone by 2-way ANOVA and Bonferroni test, n = 8–10.
doi:10.1371/journal.pone.0124510.g002
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degree of demyelination in EAE mice than in the control group (Fig 4B). However, this loss of
myelin was attenuated by TM5484. In fingolimod treated mice, demyelination was also re-
duced. These results demonstrate that PAI-1 inhibitor TM5484 reduces the foci of demyelin-
ation and cell infiltration in the spinal cord of EAE mice. Interestingly, previous in vivo studies
Fig 3. Gene expressions. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of Tnf-1, PAI-1, Cd68, Ccl2, il-6 and BDNF in spinal cord.
EAEmice show an increased expression of proinflammatory cytokines as well as a decreased expression of BDNF in spinal cord. Fingolimod has no effects
on expressions of PAI-1 and BDNF. Expression levels of all markers are normalized to b-actin. Data are shown as the means and corresponding SEM.
**P<0.01 by 1-way ANOVA and Dunnett test, n = 6–7
doi:10.1371/journal.pone.0124510.g003
PAI-1 Inhibitor Protects against Demyelination and Neuroinflammation
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have demonstrated a similar attenuation of demyelination in the spinal cord of PAI-1 KO mice
[6].
To test whether TM5484 could also protect brain tissue by preserving axons from damage,
we performed histopathological analysis of the spinal cord with SMI-32, a marker of non-phos-
phorylated neurofilament indicating axonal damage. Increased amount of axonal degeneration
was noted in the spinal cord of EAE mice at dpi 28 (Fig 4C). Yet, this was ameliorated by
TM5484 treatment to an extent similar to that observed in the fingolimod-treated mice. The
causes and pathogenesis of axonal degeneration, a feature common to many neurological dis-
orders are still obscure, but a growing body of information indicates that both inflammation
and demyelination play a major role; more specifically, microglia and macrophages, the main
effectors of the innate immune response in the CNS, might be involved in axonal damage
[26,27]. Taken together, these results suggest that PAI-1 inhibitor TM5484 could ameliorate
axonal damage probably by attenuation of the immune response. Next, we also analyzed base-
ment membrane proteins in the spinal cord. Deposition of collagen IV was increased in EAE
untreated mice (Fig 4D). Both TM5484 and fingolimod however, were able to ameliorate colla-
gen IV deposition in the spinal cord. This data highlights the possible changes of the extracellu-
lar matrix that occur in MS. Finally, fibrin deposition in spinal cord of EAE mice was also
performed. TM5484 did not affect on the amount of fibrin deposition (S5 Fig), suggesting that
PAI-1 enhanced by EAE might affect on the infiltration of inflammatory cells to a higher de-
gree than extra cellular matrix components.
Fig 4. Histological analysis. Representative photomicrographs of control, vehicle, TM5484 (5 mg/kg/d) and fingolimod (0.5 mg/kg/d) sections at dpi. 28.
Spinal cord was sectioned and stained with Cd11b (A), MBP (B), SMI-32 (C) and Collagen IV (D). Four sections of the spinal cord (lumbar spinal segments)
from each group were examined. Data are expressed as the mean and corresponding SEM. TM5484 significantly reduced macrophage infiltration/microglia
activation, demyelination, axonal degeneration as well as deposition of collagen IV in the spinal cord.
doi:10.1371/journal.pone.0124510.g004
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TM5484 delays the onset of paralysis and has additive benefit on
fingolimod
When administered from dpi 0 as a preventive treatment, TM5484 not only attenuated motor
paralysis to a minimum score but also delayed the onset of signs in EAE mice (Fig 5A). Next,
we analyzed a possible additive effect of TM5484 to fingolimod. As 0.5 mg/kg is the maximum
therapeutic dose for fingolimod, we decided to use 10 mg/kg for TM5484 (the maximum thera-
peutic dose corroborated in our preliminary studies). Addition of TM5484 10 mg/kg to fingoli-
mod, from the onset of signs in a combined treatment, attenuated the paralysis score to a
greater extent than either drug alone (Fig 5B). Similarities to previously reported in vivo studies
using t-PA as well as PAI-1 deficient mice [3,6] indicate that the beneficial effects of PAI-1 in-
hibitor TM5484 against paralysis in EAE mice are similar to the genetic knockout mice.
TM5484 attenuates paralysis score in the rat MS model
TM5484 treatment was also investigated in a rat model of EAE. Although the Lewis rat EAE
may not be considered to be a demyelinating model, we have also used it to test TM5484, as
some compounds exert a beneficial effect on mice but not in rats. Because all animals fully re-
covered by dpi. 21, the potential benefits of the drugs were measured at the peak of the paralysis
(Fig 6). TM5484 (5 mg/kg/d), initiated at the onset of signs, was associated with a significant
reduction of the paralysis score below that of EAE rats, in a similar manner seen with fingoli-
mod treatment.
Discussion
MS is the most common autoimmune inflammatory, demyelinating disease of the CNS [1]. Is
often clinically punctuated by attacks and remissions with slowly progressive disability. Based
upon the relation between PAI-1 and MS progression, we investigated the effects of a low mo-
lecular PAI-1 inhibitor, TM5484, and found that significantly attenuated neurological dysfunc-
tion in a mice model of MS as measured by the paralysis score.
Access to the CNS is essential to permit the effects of most neurotherapeutics. Lipophilicity
and polar surface area are the most relevant determinants influencing brain penetration [28].
In order to improve the low CNS penetrance of our previous series of PAI-1 inhibitors, we sys-
tematically optimized their molecular structure and tested them in an in vitro model of BBB.
Eventually, we found that PAI-1 inhibitors TM5441 and TM5484 exhibited the physicochemi-
cal properties needed by CNS-penetrant drugs. Because TM5484 demonstrated the highest
penetration ratio, we focused on this compound in the present study.
TM5484 effectively suppressed the expression of proinflammatory cytokines implicated in
MS and other neurodegenerative disorders [29]. Simultaneously, focal demyelination, axonal
degeneration and collagen IV deposition decreased. The effects of TM5484 were not limited to
the CNS, as it also down-regulated the expression of cytokines and up-regulated Il-10 in spleen
of EAE mice, showing a modulation of the immune system in the periphery as well. Like this, it
could be possible that TM5484 not only ameliorates the activation of resident microglia within
the CNS but also prevents the migration of macrophage from periphery to the CNS.
Although it has been shown that pre treatment with a peptide derived from the PAI-1 pro-
tein inhibit EAE by immunosuppression [30], at present there is still a lack of evidence on how
pharmacological inhibition of PAI-1 could reduce the loss of myelin and diminish the axonal
degeneration typically seen during the course of EAE. The heterogeneous distribution of axonal
damage in spinal cord, illustrated in our histological analysis, can also be seen when active de-
myelination occur and is consistent with a causal relationship between inflammation and
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axonal injury. Axonal damage is also likely to be multifactorial as numerous mediators of the
cellular immune response are capable to damage axons [31]. Activated macrophages and
microglia release nitric oxide, which causes reversible conduction block in demyelinated axons
[32]. Attenuation of inflammation by TM5484 might thus protect axons by impeding the re-
lease of toxic soluble mediators.
Collagen IV is restricted to vascular basement membrane in the CNS of normal adults [33];
the expression of basement membrane components is altered in MS. Although is unclear how
Fig 5. Clinical score (Preventive and combined therapy).Mice were injected with myelin oligodendrocyte glycoprotein35-55 peptide in an equal volume of
complete Freund’s adjuvant. A, Administration of TM5484 (5 mg/kg/d) from day 0 not only abolished paralysis but also delayed the onset of symptoms in EAE
mice. **P<0.01 or ***P<0.001 Vehicle vs TM5484, †P < 0.01, ‡P < 0.001 Vehicle vs Fingolimod by 2-way ANOVA and Bonferroni test, n = 8–10. B,
Simultaneous administration of TM5484 (10 mg/kg/d) with fingolimod (0.5 mg/kg/d) attenuates the clinical score to a significantly greater extent than either
TM5484 or fingolimod alone. Data are shown as the means and corresponding SEM. *P<0.05 or ***P<0.001 Fingolimod vs TM5484 + Fingolimod, by 2-way
ANOVA and Bonferroni test, n = 8–10.
doi:10.1371/journal.pone.0124510.g005
Fig 6. Clinical score in the rat MSmodel.Rats were injected with myelin basic protein69-88 peptide in an equal volume of complete Freund’s adjuvant.
Administration of TM5484 (5 mg/kg/d) from the onset of symptoms significantly attenuated the paralysis score in EAE-treated rats (P<0.001 vs. vehicle at dpi.
15). Fingolimod (0.5 mg/kg) also reduced the paralysis score to a level similar to TM5484 (P<0.001 vs. vehicle at dpi. 15). The peak of the disease was
selected to analyze the paralysis score as all animals, including vehicle, had an almost complete recovery by day 22. Data are shown as the means and
corresponding SD. *P<0.05 or ***P<0.001 Vehicle vs TM5484, †P < 0.01, ‡P < 0.001 Vehicle vs Fingolimod by 2-way ANOVA and Bonferroni test, n = 6–8.
doi:10.1371/journal.pone.0124510.g006
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TM5484 ameliorates collagen IV deposition in CNS of EAE mice, it could be also related to its
anti-inflammatory effects. For instance, van Horssen and colleagues showed that excessive de-
position of collagen IV in CNS of patients with MS might be caused by increased production of
cytokines [34]. TM5484 did not affect on the amount of fibrin deposition in spinal cord, sug-
gesting that PAI-1-enhanced by EAE might affect on the infiltration of inflammatory cells to a
higher degree than extra cellular matrix components.
There are a number of ways in which PAI-1 may contribute to the development of inflam-
mation and demyelination in the CNS. For instance, PAI-1 can act as a chemoattractant for
macrophages [10]. In the present study, gene expression and histological analyses consistently
indicated that TM5484 treatment attenuated macrophage migration and microglia activation
into the spinal cord, thereby attenuating demyelination and axonal damage.
Neurotrophic factors are known to protect neurons against various pathological insults.
For instance, BDNF is a growth factor that plays important roles in the development and main-
tenance of the nervous system and induces neuronal survival [35]. In this study, EAE mice ex-
hibited decreased mRNA expression of BDNF compared to control animals, while TM5484
treatment its BDNF expression. Inhibition of PAI-1 is predictably associated with a reciprocal
increase in the activity of its target serine protease, t-PA, with secondary increases in net plas-
min generation. Both of these serine proteases are known to convert secreted proBDNF to ma-
ture BDNF in the synaptic cleft [14]. In addition to its effects on demyelination and axonal
degeneration, TM5484 may also accelerate neuronal repair in diseases linked to decreased
BDNF levels. Although we only found differences of BDNF expression at the gene level, these
findings suggest that TM5484, directly or indirectly modulate BDNF expression in neurons
and thus might provide an additional mechanism for neuroprotection. To reinforce this,
TM5484 also up-regulated the expression of ChAT, meaning a reduction of neuronal loss in
spinal cord of EAE mice. This suggests that the effect of PAI-1 inhibitor TM5484 goes beyond
blockage of inflammation, as it also induces prevention of damage and preservation of neuro-
nal tissue. In contrast to previous studies using a mice model of Rett syndrome [36], our data
showed that fingolimod did not restore the expression of mRNA BDNF in EAE mice.
Finally, the observed benefits of TM5484 were extended experimentally in rats. Admitting
that the paralytic behavior seen in EAE rats is usually induced by infiltrating cells as well as by
edema caused by blood-brain barrier disruption rather than by demyelination [37], when
TM5484 was initiated at the time of onset of signs, motor paralysis was reduced to levels ob-
served in untreated control, indicating that TM5484 also benefits the rat model of MS.
The mechanistic understanding of MS has advanced considerably over the past decade and
has provided the rationale for the application of anti-inflammatory and immunomodulatory
treatments that can actually reduce the severity and frequency of new demyelinating episodes
[38]. Since TM5484 appears to influence several important pathogenic mechanisms in MS, it
merit further investigation and consideration as a novel therapeutic modality for the treatment
of MS.
In conclusion, we report evidence in this study that inhibition of PAI-1 with a low-molecu-
lar compound protect mice against EAE-induced inflammation, demyelination and axonal de-
generation. TM5484 represents thus a novel therapeutic approach for MS and, perhaps, other
CNS disorders.
Supporting Information
S1 Fig. Flow-chart of the identification of PAI-1 inhibitors efficiently penetrating thru the
BBB. Based on virtual screening and in silico docking simulation we first developed a new
group of oral, low molecular PAI-1 inhibitors. Among over 500 derivatives of the lead
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compound TM5275 we searched for a PAI-1 inhibitor that could efficiently penetrate into
BBB. About 50 compounds, which met the criteria for a good CNS penetration, i.e., a low MW
with a lipophilicity (clogP)< 4 and a surface area (TPSA)> 75, were selected and tested for
CNS penetration, using an in vitromodel that corresponds to the anatomical situation of cere-
bral microvessels. The penetration ratio (Papp) was finally measured. TM5484 (M.W., 384.7;
clogP, 3.07; TPSA, 108.6), a derivative of TM5441 (Boe et al 2013), exhibited the highest pene-
tration ratio across the BBB (Papp of 67.6 x 10–6 cm/s). It was selected for subsequent experi-
ments.
(EPS)
S2 Fig. Gene expression. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
of Tnf-1, IL-1b, IL-6, IL-10, IL-17 and IFNγ in spleen. EAE mice show an increased expression
of proinflammatory cytokines as well as a decreased expression of IL-10. TM5484 and fingoli-
mod were able to modulate these inflammatory effects. Expression levels of all markers are nor-
malized to b-actin. Data are shown as the means and corresponding SEM. P<0.01 by 1-way
ANOVA and Dunnett test, n = 6–7
(EPS)
S3 Fig. Gene expression. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
of ChAT in spinal cord. TM5484 as well as Fingolimod up-regulated ChAT expression com-
paring to EAE untreated mice. Expression levels of all markers are normalized to b-actin. Data
are shown as the means and corresponding SEM. P<0.01 by 1-way ANOVA and Dunnett
test, n = 5–6
(EPS)
S4 Fig. In spinal cord of control mice, expression of Iba-1 marker shows low levels of
microglia activation, as demonstrated by none ramified branches. EAE mice show an im-
portant number of microglia activated with ramified branches (green). However, this was ame-
liorated by TM5484 and fingolimod. Nuclear Dapi staining (blue) confirmed the presence of
viable cells.
(PDF)
S5 Fig. Immunostaining. Fibrinogen deposition in spinal cord of EAE mice shows no differ-
ence in comparison to control. In addition, no changes were observed after treatment with
TM5484 or fingolimod. Red asterix indicates central canal.
(PDF)
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